ReIGNITE Therapeutics focuses on developing high-capacity evolved vectors for genetic medicines, which are designed to enhance the delivery and efficacy of therapeutic genes. These advanced vectors are engineered to carry larger genetic payloads compared to traditional viral vectors, allowing for more complex and effective treatments. The company aims to address various genetic disorders by utilizing these innovative delivery systems, which can potentially improve patient outcomes through more efficient gene therapy solutions.

In addition to their vector technology, ReIGNITE Therapeutics is committed to advancing the science behind genetic medicine. Their research emphasizes the importance of optimizing vector design and functionality to ensure safe and effective gene delivery. By leveraging their expertise in vector evolution and genetic engineering, the company seeks to create transformative therapies that can tackle a range of diseases, ultimately contributing to the future of precision medicine.

United States

ReIGNITE is a biotechnology company using Directed Evolution to develop systemic high-capacity viral vector immunotherapies and gene therapies. Our unique platform leverages the Nobel Prize-winning technologies of Directed Evolution to develop customized high-capacity vectors with tissue-specific tropism.

ReIGNITE Therapeutics

Company Details